New treatment strategy for bone metastases from breast cancer

Breast Cancer ◽  
1999 ◽  
Vol 6 (4) ◽  
pp. 292-297 ◽  
Author(s):  
Norio Kohno ◽  
Sohei Kitazawa ◽  
Muneharu Konishi ◽  
Kazuyuki Wakita ◽  
Yoshihiko Furuya ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Metastases ◽  
Treatment Strategy ◽  
New Treatment

scholarly journals PTH1R-CaSR Cross Talk: New Treatment Options for Breast Cancer Osteolytic Bone Metastases

2018 ◽  
Vol 2018 ◽  
pp. 1-8 ◽  
Author(s):  
Yanmei Yang ◽  
Bin Wang
Keyword(s):  
Breast Cancer ◽  
Bone Metastases ◽  
Treatment Options ◽  
Bone Destruction ◽  
Metastatic Breast ◽  
Tumor Burden ◽  
Skeletal Metastases ◽  
Vicious Cycle ◽  
Calcium Sensing ◽  
New Treatment

Metastatic breast cancer (BrCa) is currently incurable despite great improvements in treatment of primary BrCa. The incidence of skeletal metastases in advanced BrCa occurs up to 70%. Recent findings have established that the distribution of BrCa metastases to the skeleton is not a random process but due to the favorable microenvironment for tumor invasion and growth. The complex interplay among BrCa cells, stromal/osteoblastic cells, and osteoclasts in the osseous microenvironment creates a bone-tumor vicious cycle (a feed-forward loop) that results in excessive bone destruction and progressive tumor growth. Both the type 1 PTH receptor (PTH1R) and extracellular calcium-sensing receptor (CaSR) participate in the vicious cycle and influence the skeletal metastatic niche. Thus, this review focuses on how the PTH1R and CaSR signaling pathways interact and contribute to the pathogenesis of BrCa bone metastases. The effects of intermittent PTH and allosteric modulators of CaSR for the use of bone-anabolic agents and prevention of BrCa bone metastases constitute a proof of principle for therapeutic consideration. Understanding the interplay between PTH1R and CaSR signaling in the development of BrCa bone metastases could lead to a novel therapeutic approach to control both osteolysis and tumor burden in the bone.

scholarly journals Combined inhibition of Aurora A and p21-activated kinase 1 as a new treatment strategy in breast cancer

2019 ◽  
Vol 177 (2) ◽  
pp. 369-382 ◽  
Author(s):  
Vladislav Korobeynikov ◽  
Michelle Borakove ◽  
Yayi Feng ◽  
William M. Wuest ◽  
Alex B. Koval ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Treatment Strategy ◽  
Aurora A ◽  
New Treatment ◽  
P21 Activated Kinase

scholarly journals Kadsurenone is a useful and promising treatment strategy for breast cancer bone metastases by blocking the PAF/PTAFR signaling pathway

2018 ◽  
Author(s):  
Tianhui Hou ◽  
Yan Lou ◽  
Shichang Li ◽  
Chenglong Zhao ◽  
Yingzheng Ji ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Metastases ◽  
Signaling Pathway ◽  
Treatment Strategy ◽  
Promising Treatment

Pemetrexed: A promising new treatment for breast cancer

2002 ◽  
Vol 29 (2 Suppl 5) ◽  
pp. 36-41 ◽  
Author(s):  
Joyce A. O'Shaughnessy ◽  
Alessandra Gennari ◽  
PierFranco Conte
Keyword(s):  
Breast Cancer ◽  
New Treatment
Sign in / Sign up

Export Citation Format

Share Document